<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02603562</url>
  </required_header>
  <id_info>
    <org_study_id>ATYR1940-C-003</org_study_id>
    <secondary_id>2014-003346-27</secondary_id>
    <nct_id>NCT02603562</nct_id>
  </id_info>
  <brief_title>Evaluate Safety and Biological Activity of ATYR1940 in Patients With Early Onset Facioscapulohumeral Muscular Dystrophy</brief_title>
  <acronym>FSHD</acronym>
  <official_title>An Open-Label, Intrapatient Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Early Onset and Other Pediatric Onset Facioscapulohumeral Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>aTyr Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>aTyr Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and biological activity of ATYR1940 in
      patients with early onset facioscapulohumeral muscular dystrophy (FSHD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 1b/2 open-label, intrapatient dose escalation study aiming to evaluate the safety,
      tolerability, immunogenicity, biological and pharmacodynamic activity of intravenous
      ATYR1940, administered once weekly for 12 weeks, in early onset FSHD patients with signs or
      symptoms prior to 10 years of age. In Stage 1, up to 8 patients between the ages of 16 and 25
      years will be enrolled. Stage 2 of enrollment will include patients with early onset FSHD
      between the ages of 12 and 15 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 30, 2016</start_date>
  <completion_date type="Actual">February 14, 2017</completion_date>
  <primary_completion_date type="Actual">December 13, 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidences of Treatment-Emergent adverse events and serious adverse events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Incidences of adverse events including serious and severe adverse events overall and by intensity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from Baseline in safety laboratory test results</measure>
    <time_frame>Changes from Baseline after 12 weeks</time_frame>
    <description>Changes from Baseline in safety laboratory test results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from Baseline in pulmonary evaluation</measure>
    <time_frame>Changes from Baseline after 12 week</time_frame>
    <description>Change from Baseline in pulmonary evaluation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from Baseline in visual assessment</measure>
    <time_frame>Changes from Baseline after 12 weeks</time_frame>
    <description>Changes in Baseline in visual acuity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from Baseline in hearing</measure>
    <time_frame>Changes from Baseline after 12 weeks</time_frame>
    <description>Safety Primary Outcome Measure - Changes from Baseline in hearing based on audiometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Outcome Measure - Incidence and level of ADA</measure>
    <time_frame>12 weeks</time_frame>
    <description>Incidence and level of ADA titers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Outcome Measure - Incidence and level of Jo-1 Ab</measure>
    <time_frame>12 weeks</time_frame>
    <description>Incidence and level of Jo-1 Ab titers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Outcome Measure - Incidence of infusion reactions</measure>
    <time_frame>12 weeks</time_frame>
    <description>Incidence of infusion reactions</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacodynamic Additional Outcome Measure - Changes in FSHD-related inflammatory immune state</measure>
    <time_frame>12 weeks</time_frame>
    <description>Effects assessed by changes in muscular dystrophy-related inflammatory immune state in peripheral blood</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacodynamic Additional Outcome Measure - Changes from baseline clinical parameters</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes from baseline in muscle strength based on manual muscle strength</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Facioscapulohumeral Muscular Dystrophy (FSHD)</condition>
  <arm_group>
    <arm_group_label>ATYR1940</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intrapatient dose escalation ATYR1940: ATYR1940 will be administered as an IV infusion at doses of 0.3, 1.0, and 3.0 mg/kg for up to 12 Weeks. The dose level in this study will not exceed 3.0 mg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>An initial IV infusion of placebo will be supplied as normal saline, and administered over a 30-minute period at Week 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ATYR1940</intervention_name>
    <description>ATYR1940 will be administered as an IV infusion at doses of 0.3, 1.0, and 3.0 mg/kg using intrapatient dose escalation. The dose level in this study will not exceed 3.0 mg/kg</description>
    <arm_group_label>ATYR1940</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>An initial IV infusion of placebo will be supplied as normal saline, and administered over a 30-minute period at Week 1.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Established, genetically confirmed diagnosis of FSHD.

          -  Onset of FSHD signs or symptoms prior to 10 years of age, as documented in the
             patient's medical record or based on patient or family report.

          -  Provide written informed consent or assent

          -  In the Investigator's opinion, patient is willing and able to complete all study
             procedures and comply with the weekly study visit schedule.

        Exclusion Criteria:

          -  Currently receiving treatment with an immunomodulatory agent including targeted
             biological therapies within the 3 months before baseline; corticosteroids within 3
             months before baseline; or high-dose non-steroidal anti-inflammatory agents within 2
             weeks before baseline.

          -  Currently receiving curcumin or albuterol; use of a product that putatively enhances
             muscle growth or activity on a chronic basis within 4 weeks before baseline; statin
             treatment initiation or significant adjustment to statin regimen within 3 months
             before baseline (stable, chronic statin use is permissible).

          -  Use of an investigational product or device within 30 days before baseline.

          -  Evidence of an alternative diagnosis other than FSHD or a coexisting myopathy or
             dystrophy, based on prior muscle biopsy or other available investigations.

          -  History of severe restrictive or obstructive lung disease, or evidence for
             interstitial lung disease on screening chest radiograph.

          -  History of anti-synthetase syndrome, prior Jo-1 Ab-positivity, or a positive or
             equivocally positive Jo-1 Ab test result during screening.

          -  Chronic infection, such as hepatitis B, hepatitis C, or human immunodeficiency virus
             or a history of tuberculosis.

          -  Vaccination within 8 weeks before baseline or vaccination is planned during study
             participation.

          -  Symptomatic cardiomyopathy or severe cardiac arrhythmia, that may, in the
             Investigator's opinion, limit the patient's ability to complete the study protocol.

          -  Muscle biopsy within 30 days before baseline.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kelly Blackburn</last_name>
    <role>Study Director</role>
    <affiliation>aTyr Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Children's Hospital</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OSU Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre d'nvestigation Clinique - Centre de Pharmacologie Clinique et d'Evaluations Th√©rapeutiques (CICCPCET)</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Myologie</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2015</study_first_submitted>
  <study_first_submitted_qc>November 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2015</study_first_posted>
  <last_update_submitted>May 15, 2017</last_update_submitted>
  <last_update_submitted_qc>May 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FSHD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Facioscapulohumeral</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

